地理的萎縮(GA)治療薬の世界市場:疫学予測

◆英語タイトル:Geographic Atrophy (GA) - Epidemiology Forecast to 2030
◆商品コード:DELV20JU201
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年6月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後最大10営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(201名様閲覧)USD3,750 ⇒換算¥393,750見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥590,625見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Geographic Atrophy (GA) – Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Geographic Atrophy (GA) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2017-2030

Geographic Atrophy (GA) Understanding
Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD). Macular degeneration also called age-related macular degeneration (AMD or ARMD) is a medical condition that may result in blurred or no vision in the center of the visual field. There are two basic types of macular degeneration: “dry” and “wet”. According to the “American Macular Degeneration Foundation,” approximately 85–90% of the cases of macular degeneration are the “dry” (atrophic) type.

GA is a progressive, irreversible and blinding disease that tends to affect both eyes. Nearly two-thirds geographic atrophy cases are reported in the people aged 80 years and above. GA is responsible for ~20% of all cases of legal blindness in the US and 26% of cases in the UK.

GA is characterized by one or more distinct dark patches on the retina, with corresponding areas of reduced vision or ‘blind spots’. These dark patches represent the death of different cell types in the retina, including the light-sensitive photoreceptors.

The development of imaging technologies has contributed to the understanding of the genesis and pathophysiological mechanisms of GA secondary to AMD. At present, to distinguish GA from other forms of dry AMD, color fundus photography and biomicroscopy FA examination are used. In addition to this, modern in vivo imaging technology, such as spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) allows for non-invasive and rapid quantitative morphological assessment of GA in the clinical setting also being used for GA.

Geographic Atrophy (GA) Epidemiology Perspective by DelveInsight
The GA epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The GA epidemiology data are studied through GA possible division to give a better understanding of the Disease scenario in the 7MM.

The disease epidemiology covered in the report provides historical as well as forecasted GA epidemiology [segmented as Total Prevalent Cases of GA, Total Diagnosed Cases of GA, Total Diagnosed cases of GA by Age Distribution, Total Geographic Atrophy Cases by Visual Impairment, and Total Treated Cases of GA] scenario of GA in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

Geographic Atrophy (GA) Detailed Epidemiology Segmentation
The total prevalent cases of GA in the 7MM were found to be 2,726,453 in 2017 which is expected to grow during the study period, i.e., 2017–2030.
In the 7MM, the total diagnosed cases of GA were 2,516,401 cases in 2017.
The highest number of diagnosed prevalent cases was observed in the United States. On the other hand, in EU-5 countries, the highest number of diagnosed prevalent cases of GA was found in the UK with 282,917cases in 2017, followed by France and Germany. Spain accounted for the least number of diagnosed prevalent cases in the 7MM. Also, Japan accounted for 173,465 diagnosed prevalent cases in 2017.
In age-specific cases of GA, in 2017, the most number of cases (i.e. nearly two-thirds) was seen in patients of age ≥80 years, followed by the age-group of 75–79 years and 70–74 years.
In total GA cases by visual impairment, most of the cases (i.e. around 50%) were moderate to severe impairment followed by mild. Patients having moderate to severe visual impairment were accounted for 1,258,200 cases in 2017.
Scope of the Report
The Geographic Atrophy (GA) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
The Geographic Atrophy (GA) Epidemiology Report and Model provide an overview of the risk factors and global trends of Geographic Atrophy (GA) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight about the historical and forecasted patient pool of Geographic Atrophy (GA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Geographic Atrophy (GA)
The report provides the segmentation of the Geographic Atrophy (GA) epidemiology

Report Highlights
11-Year Forecast of Geographic Atrophy (GA) epidemiology
7MM Coverage
Total Cases of Geographic Atrophy (GA)
Total Cases of Geographic Atrophy (GA) according to segmentation
Diagnosed cases of Geographic Atrophy (GA)

KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Geographic Atrophy (GA)?
What are the key findings pertaining to the Geographic Atrophy (GA) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
What would be the total number of patients of Geographic Atrophy (GA) across the 7MM during the forecast period (2017-2030)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
What is the disease risk, burden and unmet needs of the Geographic Atrophy (GA)?
What are the currently available treatments of Geographic Atrophy (GA)?

Reasons to buy
The Geographic Atrophy (GA) Epidemiology report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the global Geographic Atrophy (GA) market
Quantify patient populations in the global Geographic Atrophy (GA) market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Geographic Atrophy (GA) therapeutics in each of the markets covered
Understand the magnitude of Geographic Atrophy (GA) population by its epidemiology
The Geographic Atrophy (GA) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

【レポートの目次】

1. Key Insights

2. Executive Summary of Geographic Atrophy (GA)

3. Geographic Atrophy (GA): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Geographic Atrophy (GA) Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Geographic Atrophy (GA) Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Geographic Atrophy (GA) Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Geographic Atrophy (GA) Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Geographic Atrophy (GA) Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Geographic Atrophy (GA) Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Geographic Atrophy (GA) Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Geographic Atrophy (GA) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Geographic Atrophy (GA) Treatment and Management

6.2. Geographic Atrophy (GA) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1: Summary of GA Epidemiology (2017–2030)

Table 2: The four-stage classification of AMD from the Age-Related Eye Disease Study (AREDS)

Table 3: AREDS Risk Factor Scoring System

Table 4: Total Prevalent Cases of Geographic Atrophy in the 7MM (2017–2030)

Table 5: Total Diagnosed cases of Geographic Atrophy in the 7MM (2017–2030)

Table 6: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the 7MM (2017–2030)

Table 7: Total Geographic Atrophy Cases by Visual Impairment in the 7MM (2017–2030)

Table 8: Total Treated cases of Geographic Atrophy in the 7MM (2017–2030)

Table 9: Total Prevalent Cases of Geographic Atrophy in the United States (2017–2030)

Table 10: Total Diagnosed cases of Geographic Atrophy in the United States (2017–2030)

Table 11: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United States (2017–2030)

Table 12: Total Geographic Atrophy Cases by Visual Impairment in the US (2017–2030)

Table 13: Total Treated cases of Geographic Atrophy in the US (2017–2030)

Table 14: Total Prevalent Cases of Geographic Atrophy in Germany (2017–2030)

Table 15: Total Diagnosed cases of Geographic Atrophy in Germany (2017–2030)

Table 16: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Germany(2017–2030)

Table 17: Total Geographic Atrophy Cases by Visual Impairment in Germany (2017–2030)

Table 18: Total Treated cases of Geographic Atrophy in Germany (2017–2030)

Table 19: Total Prevalent Cases of Geographic Atrophy in France (2017–2030)

Table 20: Total Diagnosed cases of Geographic Atrophy in France (2017–2030)

Table 21: Total Diagnosed cases of Geographic Atrophy by Age Distribution in France (2017–2030)

Table 22: Total Geographic Atrophy Cases by Visual Impairment in France (2017–2030)

Table 23: Total Treated cases of Geographic Atrophy inFrance (2017–2030)

Table 24: Total Prevalent Cases of Geographic Atrophy in Italy (2017–2030)

Table 25: Total Diagnosed cases of Geographic Atrophy in Italy (2017–2030)

Table 26: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Italy (2017–2030)

Table 27: Total Geographic Atrophy Cases by Visual Impairment in Italy (2017–2030)

Table 28: Total Treated cases of Geographic Atrophy in Italy (2017–2030)

Table 29: Total Prevalent Cases of Geographic Atrophy in Spain (2017–2030)

Table 30: Total Diagnosed cases of Geographic Atrophy in Spain (2017–2030)

Table 31: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Spain (2017–2030)

Table 32: Total Geographic Atrophy Cases by Visual Impairment in Spain (2017–2030)

Table 33: Total Treated cases of Geographic Atrophy in Spain (2017–2030)

Table 34: Total Prevalent Cases of Geographic Atrophy in the United Kingdom (2017–2030)

Table 35: Total Diagnosed cases of Geographic Atrophy in the United Kingdom (2017–2030)

Table 36: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United Kingdom (2017–2030)

Table 37: Total Geographic Atrophy Cases by Visual Impairment in UK (2017–2030)

Table 38: Total Treated cases of Geographic Atrophy in the UK (2017–2030)

Table 39: Total Prevalent Cases of Geographic Atrophy in Japan(2017–2030)

Table 40: Total Diagnosed cases of Geographic Atrophy in Japan(2017–2030)

Table 41: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Japan (2017–2030)

Table 42: Total Geographic Atrophy Cases by Visual Impairment in Japan (2017–2030)

Table 43: Total Treated cases of Geographic Atrophy in Japan (2017–2030)



Figure 1: Geographic Atrophy (GA) SWOT Analysis

Figure 2: Dry AMD and Wet AMD

Figure 3: AREDS Risk Factor Scoring System

Figure 4: Stages of AMD

Figure 5: Signs and Symptoms of GA

Figure 6: Risk Factors of GA

Figure 7: Impact of GA progression on patient vision

Figure 8: Pathophysiology of GA

Figure 9: Classical, Lectin, and Alternative Complement Cascade-mediated Pathway

Figure 10: Complement Cascade-mediated Pathway

Figure 11: Assessment of GA

Figure 12: Characteristics of GA across different imaging technique

Figure 13: Progression of GA illustrated with high-resolution SD-OCT over a period of 14 months

Figure 14: Progression of GA illustrated by FAF imaging and GA quantification over time

Figure 15: Semi-automated quantification of GA by means of image analysis software (Region-Finder)

Figure 16: Total Prevalent Cases of Geographic Atrophy in the 7MM (2017–2030)

Figure 17: Total Diagnosed cases of Geographic Atrophy in the 7MM (2017–2030)

Figure 18: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the 7MM (2017–2030)

Figure 19: Total Geographic Atrophy Cases by Visual Impairment in the 7MM (2017–2030)

Figure 20: Treated cases of Geographic Atrophy in the 7MM (2017–2030)

Figure 21: Total Prevalent Cases of Geographic Atrophy in the United States (2017–2030)

Figure 22: Total Diagnosed cases of Geographic Atrophy in the United States(2017–2030)

Figure 23: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United States (2017–2030)

Figure 24: Total Geographic Atrophy Cases by Visual Impairment in the US (2017–2030)

Figure 25: Treated cases of Geographic Atrophy in the United States (2017–2030)

Figure 26: Total Prevalent Cases of Geographic Atrophy in Germany (2017–2030)

Figure 27: Total Diagnosed cases of Geographic Atrophy in Germany (2017–2030)

Figure 28: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Germany(2017–2030)

Figure 29: Total Geographic Atrophy Cases by Visual Impairment in Germany (2017–2030)

Figure 30: Treated cases of Geographic Atrophy in Germany (2017–2030)

Figure 31: Total Prevalent Cases of Geographic Atrophy in France (2017–2030)

Figure 32: Total Diagnosed cases of Geographic Atrophy in France(2017–2030)

Figure 33: Total Diagnosed cases of Geographic Atrophy by Age Distribution in France (2017–2030)

Figure 34: Total Geographic Atrophy Cases by Visual Impairment in France (2017–2030)

Figure 35: Treated cases of Geographic Atrophy in France (2017–2030)

Figure 36: Total Prevalent Cases of Geographic Atrophy in Italy (2017–2030)

Figure 37: Total Diagnosed cases of Geographic Atrophy in Italy (2017–2030)

Figure 38: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Italy (2017–2030)

Figure 39: Total Geographic Atrophy Cases by Visual Impairment in Italy (2017–2030)

Figure 40: Treated cases of Geographic Atrophy in Italy (2017–2030)

Figure 41: Total Prevalent Cases of Geographic Atrophy in Spain (2017–2030)

Figure 42: Total Diagnosed cases of Geographic Atrophy in Spain (2017–2030)

Figure 43: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Spain (2017–2030)

Figure 44: Total Geographic Atrophy Cases by Visual Impairment in Spain (2017–2030)

Figure 45: Treated cases of Geographic Atrophy in Spain (2017–2030)

Figure 46: Total Prevalent Cases of Geographic Atrophy in the United Kingdom (2017–2030)

Figure 47: Total Diagnosed cases of Geographic Atrophy in the United Kingdom(2017–2030)

Figure 48: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United Kingdom (2017–2030)

Figure 49: Total Geographic Atrophy Cases by Visual Impairment in the UK (2017–2030)

Figure 50: Treated cases of Geographic Atrophy in the United Kingdom (2017–2030)

Figure 51: Total Prevalent Cases of Geographic Atrophy in Japan (2017–2030)

Figure 52: Total Diagnosed cases of Geographic Atrophy in Japan(2017–2030)

Figure 53: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Japan (2017–2030)

Figure 54: Total Geographic Atrophy Cases by Visual Impairment in Japan (2017–2030)

Figure 55: Treated cases of Geographic Atrophy in Japan (2017–2030)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[地理的萎縮(GA)治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆